Patent intelligence · US
US 2012301425
NOVEL ANTITUMORAL USE OF CABAZITAXEL
NOVEL ANTITUMORAL USE OF CABAZITAXEL
Patent details — US 2012301425
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 29, 2012
- Expiration
- Nov 24, 2032
- Applicant
- GUPTA SUNIL [US]
- CPC classes
- A61K 31/ 56 A I, A61K 31/ 164 A I, A61K 31/ 337 A I, A61K 31/ 573 A I
Quick answer
US 2012301425 (NOVEL ANTITUMORAL USE OF CABAZITAXEL) is held by GUPTA SUNIL [US]. Status: granted. Granted Nov 29, 2012. Expires Nov 24, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- GUPTA SUNIL [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 56 A I, A61K 31/ 164 A I, A61K 31/ 337 A I, A61K 31/ 573 A I, A61K 38/ 19 A I, A61K 45/ 06 A I
More from GUPTA SUNIL [US]
Related pharmaceutical patents in our USPTO index.
-
EP 3093014
CABAZITAXEL UND DESSEN VERWENDUNG ZUR BEHANDLUNG VON KREBS
granted -
WO 2015104417
UTILISATION DU CABAZITAXEL POUR LE TRAITEMENT DE L'ADÉNOCARCINOME GASTRIQUE
granted -
WO 2015036507
UTILISATION DE CABAZITAXEL CHEZ DES PATIENTS CHEZ QUI UN CANCER DU POUMON NON À PETITES CELLULES MÉTASTATIQUE CONTINUE À PROGRESSER APRÈS UN TRAITEMENT À BASE DE DOCÉTAXEL
granted -
CA 2903132
CABAZITAXEL ET SON UTILISATION POUR LE TRAITEMENT DES CANCERS DE LA PROSTATE METASTATIQUES
granted -
EP 2678011
ANTITUMORIGENE KOMBINATON, DIE CABAZITAXEL UND CISPLATIN UMFASST
granted -
EP 2656851
Semuloparin zur Verbesserung der Überlebenschance von Krebspatienten
granted -
CA 2864029
NOUVELLES UTILISATIONS PEDIATRIQUES DU CABAZITAXEL
granted -
EP 2620148
Antitumorkombination mit Cabazitaxel und Cisplatin
granted
Frequently asked questions
What is US patent 2012301425?
US 2012301425 (NOVEL ANTITUMORAL USE OF CABAZITAXEL) is held by GUPTA SUNIL [US]. Status: granted. Granted Nov 29, 2012. Expires Nov 24, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2012301425?
GUPTA SUNIL [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 2012301425 expire?
Our index shows an expiration date of Nov 24, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.